.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
GPR84 receptor antagonists are now a focal point in drug discovery for chronic inflammation and fibrotic tissue remodeling. GPR84 is a metabolite-sensing Class A GPCR primarily expressed on myeloid immune cells. Its activation by medium-chain fatty acids triggers a pro-inflammatory cascade. Consequently, inhibiting this pathway offers a novel approach to treating conditions like inflammatory bowel disease and idiopathic pulmonary fibrosis.
Recent patent filings from 2020 to 2026 reveal an expansion in the chemical diversity of GPR84 modulators. Researchers are developing more selective and potent molecules. While candidates like GLPG1205 paved the way, newer molecules such as BGT-004 are now under scrutiny. Furthermore, these advancements demonstrate a concerted effort to optimize oral bioavailability for better patient compliance. However, development remains volatile. For example, the candidate BAY-3178275 recently faced discontinuation in Phase 1 trials for diabetic neuropathic pain. This setback highlights the biological complexities inherent in targeting this receptor.
Clinical translation of GPR84 receptor antagonists still faces significant hurdles. Specifically, uncertainty regarding the receptor's primary endogenous ligand persists. Furthermore, its role in various tissue microenvironments remains complex and not fully understood. Nevertheless, its inducible nature in disease states makes it a highly specific inflammation sensor. Consequently, future progress depends on identifying patient endotypes who will benefit most from GPR84 modulation. Deeper mechanistic insights are therefore essential to move these patent-stage molecules into clinical practice.
Researchers are investigating these antagonists for inflammatory and fibrotic disorders. Key interests include ulcerative colitis, non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis.
GPR84 acts as an amplifier of the innate immune response. When activated by fatty acids, it promotes the chemotaxis of neutrophils and macrophages. This process leads to sustained pro-inflammatory signaling in damaged tissues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Recent patent reviews show expanding chemical diversity in GPR84 receptor antagonists for treating inflammatory and fibrotic diseases. While candidates like BGT-004 show promise, clinical challenges like the discontinuation of BAY-3178275 highlight the need for deeper mechanistic understanding.
4 weeks back
Researchers at Kyushu University have uncovered a novel compound, lipoic acid trisulfide (LASSS), that enhances hepatocyte growth factor (HGF) signaling and protects against nitration-induced protein dysfunction, presenting a potential breakthrough for age-related muscle atrophy and sarcopenia.
Yesterday
A study identifies a critical hypospadias gene-environment interaction. Research shows that the risk gene DNAH8 and DEHP exposure combine to disrupt steroidogenesis and mesenchymal progenitor cell differentiation, significantly increasing the risk of severe urethral malformations in male fetuses.
5 days back
A pre-clinical study reveals that elevated serum pro-N-cadherin levels correlate strongly with severe cardiac fibrosis and diastolic dysfunction following radiation exposure, promising a potential early biomarker for radiation-related heart disease.
3 days back
Discover how biophysical forces shape tissue formation and regeneration. This review explores mechanotransduction in tissue development, from molecular sensors like integrins to tissue-scale flows, highlighting critical implications for regenerative medicine and functional organoid engineering.
Last week
A groundbreaking study utilizes single-cell RNA sequencing to map the tumor microenvironment of ovarian steroid cell tumors-not otherwise specified (SCT-NOS), identifying key steroidogenic subtypes and immune cell distributions that drive hyperandrogenism and tumor progression.
Last week
